{"classes":[{"categories":[{"measurements":[{"comment":"Cannot be estimated due to insufficient number of events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"description":"PFS is defined as the time from the date of the first dose to the date of first PD per RECIST 1.1 criteria or death from any cause, whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"vobramitamab duocarmazine 2.7 mg.kg, IV, every 4 weeks","id":"OG000","title":"Part 2"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Every 8 weeks for the first 24 weeks, then every 12 weeks. Average duration of participation, 10 months.","title":"Part 2: Median Progression Free Survival (PFS) Per Investigator Assessment of RECIST 1.1 Criteria","type":"SECONDARY","unitOfMeasure":"months"}